After laying off most of its staff and partnering away its phase 3 cancer asset earlier this year, precision oncology outfit Repare Therapeutics has agreed to be acquired by nonprofit biotech ...

XenoTherapeutics Inc. and Xeno Acquisition Corp, a non-profit biotechnology company, on Friday agreed to acquire Repare Therapeutics Inc. (NASDAQ: RPTX). Repare shareholders will receive a cash ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min After cutting 75% of its staff ...

Taitron said it has plans to voluntarily delist its stock because costs were outweighing benefits. The stock slid 40% to $1.24 in after-hours trading Friday. Repare Therapeutics agreed to be acquired ...

Repare Therapeutics said it reached an agreement to be acquired by XenoTherapeutics, in a deal which will see shareholders receive cash and contingent value rights. Under the terms of the deal, Repare ...

- $112.6 million in cash and cash equivalents and marketable securities as of September 30, 2025, as compared to $109.5 million at June 30, 2025 - Repare Therapeutics Inc. (“Repare” or the “Company”) ...

- $112.6 million in cash and cash equivalents and marketable securities as of September 30, 2025, as compared to $109.5 million at June 30, 2025 - CAMBRIDGE, Mass. & MONTREAL, November 14, ...

Seven months after pressing pause on its plans for its PKMYT1 inhibitor, Repare Therapeutics has found a partner to take the cancer drug forward. Back in January, Repare abandoned phase 3 plans to ...

Following this transaction, Repare will focus on advancing its two ongoing Phase 1 clinical trials. The POLAR trial evaluating RP-3467, a polymerase theta inhibitor, is expected to deliver topline ...

Repare Therapeutics has entered an out-licensing agreement with Canadian biotechnology firm DCx Biotherapeutics for discovery platforms and intellectual property (IP). Repare will obtain $4m in ...

Repare Therapeutics Inc. (RPTX) stock has tumbled to a 52-week low, touching down at $0.98, as the company faces a challenging market environment. According to InvestingPro data, while the company ...

Shares of Repare Therapeutics (NASDAQ:RPTX) plunged 38% in post-market trading Thursday after the company reported Phase 1 data on its drugs lunresertib and camonsertib as a combination therapy for ...